NEOGENIX ONCOLOGY INC has a total of 18 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2002. It filed its patents most often in Canada, EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are KOLLTAN PHARMACEUTICALS INC, OXFORD BIOTHERAPEUTICS LTD and THERACLONE SCIENCES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 3 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | United States | 3 | |
#4 | WIPO (World Intellectual Property Organization) | 3 | |
#5 | Japan | 2 | |
#6 | Brazil | 1 | |
#7 | China | 1 | |
#8 | Hong Kong | 1 | |
#9 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Analysing materials | |
#5 | Sugars |
# | Name | Total Patents |
---|---|---|
#1 | Bristol J Andrew | 14 |
#2 | Kantor Judith A | 6 |
#3 | Tsang Kwong Y | 5 |
#4 | Arlen Myron | 4 |
#5 | Hollinshead Ariel C | 3 |
#6 | Wang Xue-Ping | 3 |
#7 | Kantor Judith | 3 |
#8 | Luka Janos | 3 |
#9 | Judith A Kantor | 3 |
#10 | Du Xiulian | 3 |
Publication | Filing date | Title |
---|---|---|
CA2803391A1 | Npc1 antibodies that bind a muc5ac epitope | |
EP2217625A2 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | |
US2007020273A1 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |